Summary. The 
Introduction
The production of monoclonal antibodies has greatly facilitated the analysis of the antigenic profile of human tumor cells. These studies will eventually identify markers that will be useful in the development of immunodiagnostic and immunotherapeutic approaches to malignant diseases and will contribute to our understanding of the abnormal behavior of tumor cells. Monoclonal antibodies have been extensively applied in the analysis of human melanoma cells, and through the efforts of several investigators a variety of antigens have been identified which are expressed by melanoma cells [5, 6, 9-11, 16, 22, 29, 31] but are not detectable on melanocytes [6, 9, 22, 29, 31] ; these antigens are referred to as melanoma-associated antigens (MAA). We have developed several monoclonal antibodies to human melanoma cells; in previous studies we have analyzed monoclonal antibodies to a high-molecular-weight plasma membrane-bound MAA and to a cytoplasmic MAA [22, 29] . In this study we characterize the MoAb 345.134S, which defines a membrane-bound glycoprotein with serological and structural properties distinct from those of other membrane-bound glycoproteins identified on human melanoma cells with monoclonal antibodies. Specifically, we will describe:
(1) the structure of the target antigen; (2) the distribution of the antigen in normal and malignant tissues; and (3) the expression of the antigen on cultured cells and its ability to function as a target of immune lysis.
Materials and Methods

Preparation of Monoclonal Antibodies (MoAb).
Splenocytes from a BALB/e mouse immunized with cultured melanoma cells Colo38 were fused with the routine myeloma line Sp 2/0-Ag 14 according to the hybridoma procedure described elsewhere [10, 11] . The hybridoma secreting MoAb 345.134S, selected by its strong reactivity with a panel of cultured cells, has been subcloned twice and has been propagated in vitro and in vivo for at least 1 year. Immunodiffusion analysis with rabbit anti-mouse Ig antisera (Litton Bionetics, Kensington, MD, USA) has shown that the MoAb 345.134S is of the IgG2a subclass. The monoelonal antibodies Q5/13 to human Ia-like antigens [25] , NAMB-1 to human flz-microglobulin (fl2-~t) [23] , 225.28S to a high-molecular-weight MAA [29] , and 376.96S to a 94K tumor-associated antigen [30] have been described in the indicated references. The MoAb W6/32 reactive with the heavy chain of HLA-A,B,C antigens [24] was obtained commercially (Accurate Chemical Co., Hicksville, NY USA).
Human Cells. Cells in long-term culture were maintained in RPMI 1640 medium containing 10% calf serum. Peripheral blood lymphocytes (PBL) and leukemic cells were isolated from heparinized blood by differential centrifugation on Ficoll-Hypaque and then separated into T and B cell populations by nylon wool filtration [14] . Peripheral blood monocytes were obtained by adherence to plastic in a T75 flask (Falcon Plastics, Cockeysville, MD, USA) at 37 ° C for 30 min [14] . Granulocytes were prepared from heparinized blood as described by Boyum [3] .
Melanoma cells in log phase (5 x 105/ml) were cultured with 500-2,000 IU/ml partially purified human leukocyte interferon (a generous gift of Dr. K. Cantell, Central Public Health Center, Helsinki, Finland) or with 1-5 ~tg puromycin/ml (Sigma, St. Louis, MO, USA) for 16 h at 37 ° C. The cells were then washed three times with minimum essential medium and then used in the antibody-dependent cell-mediated cytotoxicity (ADCC) assay. The interferon treatment did not affect cell viability or growth, and the effect of puromycin on protein synthesis was monitored by incorporation of 3H-proline.
Tissue Specimens. Tissues were obtained surgically from untreated patients and from patients undergoing different therapeutic regimens. Normal tissues were obtained from surgically removed neoplastic lesions. Tissue specimens were snap-frozen in liquid nitrogen and two consecutive cryostat sections of 4 ~t thickness were obtained from each frozen tissue: one section was stained with toluidine blue (0.1% in phosphate-buffered saline), while the other was fixed for 10 min in cold absolute acetone and then used in the indirect immunofluorescence (IIF) test. Absolute acetone was chosen over other fixatives because it retained the most detail after fluorescent staining.
Radiolabelling, Indirect Immunoprecipitation and Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PA GE).
Human melanoma cells were intrinsically radiolabelled with 3H-glucosamine D-[6-3H(N)] 30 mCi/mmole (New England Nuclear, Boston, MA, USA) according to the method of Duksin and Bornstein [7] or were surface-labelled with 125I (Amersham, Arlington Heights IL, USA) by the Iodogen method of Salisbury and Graham [27] . Labelled cells were extracted with 10 volumes of nonidet P40 detergent (1.0% in phosphate-buffered saline) containing 10 ~tm phenylmethylsulfonylfluoride by rotation for 30 min at 4 ° C. The extract was cleared by centrifugation at 7,000 g and stored at -20 ° C. Cell extracts performed with 3 M KCI or with urea were performed as described for NP40 and dialyzed against phosphate-buffered saline prior to use. Indirect immunoprecipiration was performed as described previously [1] , except that protein A-Sepharose 4B (Pharmacia) was used in place of the formalin-fixed bacteria, and pre-clearing of the NP40 detergent cell extract was not necessary. Briefly, 10 ~tl packed protein A Sepharose was mixed with 5 × 10 6 cpm 125I-labelled cell extract and diluted to 0.5 ml with NET buffer (50 mM Tris, 150 mM NaC1, 5 mM EDTA, 1 mg bovine serum albumin/ml, pH 7.4). After rotation for 2 h at 4 ° C, the Sepharose was washed eight times with NET buffer and then twice with phosphate-buffered saline. SDS sample buffer was added (100 ~) [18] and the Sepharose was boiled at 100 ° C for 2 rain prior to loading on an SDS-polyacrylamide gel. SDS-PAGE was performed in 80 x 1.5 mm slab gels containing an acrylamide gradient of 5%-12.5% and the SDS buffer system of Laemmli [18] . The gels containing 3H-glucosamine-labelled antigens were processed for fluorography as described by Bonner and Laskey [2] while ~25I-labelled antigens were autoradiographed at -70 ° C. Rabbit phosporylase a (94,000), bovine serum albumin (68,000), ovalbumin (44,000), carbonic anhydrase (29,000), and whale myoglobin (17,000) were used as molecular weight standards.
Binding Assays and Cell-and Complement-dependent Cytotoxicity
Assays. The IIF test was performed by a standard procedure described previously [21] . A distinct bright green fluorescent staining of the plasma membrane was used as a criterion of positive reactions of tissue sections with monoclonal antibodies. Unreactive tissue sections were tested further with concentrated (20 ~tg/ml) and diluted (0.5 ~tg/ml) solutions of the monoclonal antibody to avoid false-negative reactions attributable to either a low concentration of the monoclonal antibody or to a prozone-like effect [19] . The specificity of fluorescent staining was controlled by testing tissue sections with myeloma protein secreted by the murine myeloma cells P3-X63-Ag8 or with culture supernatants of the hybridomas 345.134S from which the monoclonal antibodies had been removed by adsorption at 4 ° C with one volume of cultured human melanoma cells (MI0). The efficiency of adsorption was confirmed by the failure of the adsorbed culture supernatant to stain cultured human melanoma cells.
The 125I-SPA radioimmunometric assay was performed in microtiter plates as described elsewhere [23] . The complement-dependent microcytotoxic test was performed as an eosin exclusion test, rabbit serum being used as the complement source [8] .
The ADCC assay was performed in 96-well microtiter plates (Cooke Laboratory Products, Alexandria, VA, USA) as described previously [13] . The percentage of specific 51Cr release from the cells was used as a measure of lysis and was calculated as follows:
where A = mean cpm of test samples, B = mean clam of counter background, C = mean cpm of antibody free control in the presence of effector cells, and T = mean cpm of total amount of 51Cr incorporated into the target cells. All test combinations were performed in triplicate with spontaneous or background leakage of 51Cr from the target cells ranging from 13% to 21% of the total incorporated radiolabel. This ll5K-dalton antigen appears to be peripheral rather than integral to the plasma membrane since it is readily solubilized under mildly denaturing conditions (10 mM phosphate buffer, 3 M KCI, 0.1 M urea) and in the absence of detergents (data not shown).
Reactivity of MoAb 345.134S with Surgically Removed Normal and Malignant Tissues and with Hematopoietic Cells
Representative patterns of IIF staining of four cryostat sections of surgically removed tissues with the MoAb 345.134S are shown in Figs. 2 and 3 . The results have been organized in Table 1 by using the criterion of whether normal tissues are reactive or unreactive with the monoclonal antibody. The following points are noteworthy: (a) the reactivity pattern of normal tissues with the MoAb 345.134S does not correlate with their embryological origin; (b) the majority of positive normal tissues gave a weak staining which could be detected only by examining tissue sections with an oil immersion objective, except for the plasma membrane of the epithelium of sebaceous glands (Fig. 2) and the basal layer of hyperpigmented skin (i.e., mammary areola and perineum), both of which were brightly stained. It should be noted that the weak fluorescence is specific since no staining occurred when the antibody solution was absorbed with cultured melanoma cells. Normal pigmented skin showed faint staining in limited areas of the basal cell layer. The nature of the cells in the basal cell layer was not identified; these cells are not likely to be melanocytes since the MoAb 345.134S did not stain melanocytes in other areas of skin from either Negro or Caucasian donors; (c)in supernates were harvested and counted in a gamma counter, after which the % 51Cr release was determined as described in Materials and Methods kidneys, the staining was limited to the plasma membrane and the cytoplasm of the epithelium of proximal tubules; (d) the reactivity pattern of tissues from a 20-week-old fetus is similar to that of normal adult tissues; (e) although normal melanocytes in sections of normal pigmented and hyperpigmented skin were unreactive with the MoAb 345.134S, the majority of intradermal (4 out of 6 cases) and compound (7 out of 8 cases) nevic cells exhibited plasma membrane fluorescence, while six blue nevi were unreactive; (f)all the types of tumors tested with the exception of liver adenocarcinomas reacted strongly with the MoAb 345.134S. However, there were some cases within each tumor group that were negative. In addition to tissue sections, the MoAb 345.134S also reacted with T and B lymphocytes, monocytes, and granulocytes from the peripheral blood of healthy donors and with chronic lymphocytic and acute myelogenous leukemic cells in the lzsI-binding assay; on the other hand, human erythrocytes were unreactive with the monoclonal antibody.
Lytic Activity of the MoAb 345.134S in Complement-and Cell-dependent Cytotoxicity of Cultured Human Cells
The MoAb 345.134S reacts in the 125I-SPA radioimmunometric assay with a variety of cell lines which include melanoma, carcinoma and lymphoid cell types. There is no relationship between the level of expression of the antigenic determinant recognized by the MoAb 345.134S and other surface markers tested (Table 2) , i.e., HLA-A,B antigens, Ia-like antigens, a 94K glycoprotein recognized by the MoAb 376.96S, and a high, molecular-weight glycoprotein recognized by the MoAb 225.28S. Furthermore, the reactivity of the MoAb 345.134S with the cell lines Daudi and with our K562 cells, both of which lack /32-# [23, 32] , is in agreement with immunochemical evidence that the structure detected by MoAb 345.134S in the SpA-radioimmunometric assay is not associated with/32-# and does not require /32-# for its expression. The level of antigen detectable on melanoma cells with the MoAb 345.134S is not affected by treatment with human leukocyte interferon (500-2,000 IU/ml), but is reduced by treatment with puromycin (5 ~g/ml) (data not shown). The MoAb 345.134S can mediate complement-and cell-dependent lysis of cultured human cells (Table  3 ). The degree of lysis in both assays does not show a relationship with the extent of binding of the MoAb 345.134S to the target cells. Furthermore, cultured cells display an increased susceptibility to cell-dependent lysis mediated by the MoAb 345.134S following treatment with doses of puromycin (1 #g/ml) which do not affect the level of expression of the target antigen (Fig. 4) . On the other hand, no change in the extent of cell-dependent lysis occurs when melanoma cells have been treated with interferon (Fig. 4) .
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Discussion
Immunochemical analysis of the specificity of the MoAb 345.134S has shown that it identifies a two-chain structure composed of an 85K-dalton glycopolypeptide disulfide-bridged to a 30K-dalton polypeptide having little if any covalently attached carbohydrate. It is not yet known whether one or both chains carry the antigenic determinant detected by MoAb 345.134S. Solubilization under various conditions showed that the antigen detected by MoAb 345.134S is peripheral rather than integral in its association with the plasma membrane.
The MoAb 345.134S was tested with human cell lines in a binding assay and with a large variety of surgically removed normal and malignant tissues in indirect immunofluorescence; the latter assay was preferred to adsorption since it allows identification of the reactive cells. Furthermore, the ability of MoAb 345.134S to immunoprecipitate the corresponding antigen suggests that it is of high affinity and therefore unlikely to cause binding negative/adsorption positive reactions, which have been reported for certain monoclonal antibodies [6] . Results of this extensive serological analysis of MoAb 345.134S show the presence of the antigen in epithelial cells of certain normal fetal and adult tissues and in a large variety of human tumors. In general, the intensity of staining is much stronger for tumor lesions than for their corresponding normal tissues, suggesting that malignant transformation of cells is associated with increased synthesis and/or reduced shedding of this antigen. A variable number of biopsies within each tumor group did not react with MoAb 345.134S. Whether this finding reflects polymorphism of the antigenic determinant defined by the MoAb 345.134S or lack of the antigenic structure in certain tumors is, however, presently unknown. Also, the clinical significance of this differential reactivity of tumors with the MoAb 345.134S cannot be assessed at this time since the number of cases tested is too low and the clinical information is insufficient to draw any firm conclusions.
The antigen detected by MoAb 345.134S appears to be different in its tissue distribution and molecular profile from the several other glycoproteins which have been identified on human cell lines. Some of the most relevant antigens will be compared here. Thus, it is different from the 90K-dalton glycoprotein described by Judd et al. [15] , since this antigen is expressed on dividing cells but is absent from non-dividing cells and monocytes and the molecule exists as a dimer of 200K daltons in its native state. It is also different from the 94K-dalton antigen identified by our MoAb 376.96S [30] , the 95K-dalton Antigen 165 antigen described by Dippold et al. [6] , and the 97K-dalton antigen described by Woodbury et al. [31] , since they are single-chain structures and they are mostly restricted to melanomas and carcinomas. The 85K-dalton glycoprotein detected by MoAb 345.134S is probably different from a 95K-dalton glycoprotein isolated from Molt 4 cells [26] , since the latter is one of the major glycoproteins synthesized by these cells while our experience suggests that the 85K glycoprotein is not so well represented on these cells. Finally, the 85K-dalton glycoprotein is distinct in tissue distribution from the common ALL antigen described by Sutherland et al. [28] and from the 100K-dalton glycoprotein found in a variety of different tumors by Bramwell and Harris [4] . The MoAb 345.134S can mediate complementand cell-dependent lysis of human tumor cells. The extent of lysis does not correlate with the level of expression of the antigenic determinant recognized by this monoclonal antibody, indicating that other variables besides antigen density play a significant role in the outcome of immune lytic reactions. This conclusion is also supported by the finding that melanoma cells treated with low doses of puromycin increase in susceptibility to cell-dependent lysis mediated by the MoAb 345.134S, although the level of cell surface target antigen remains unchanged. The amount of antigen detectable by MoAb 345.134S on melanoma cells was also unaffected by doses of interferon that result in increased levels of HLA-A,B,C antigens [12] . This result deserves some comment in view of the reported beneficial effects of interferon on the clinical course of a limited number of melanoma patients [17] . Our experience with monoclonal antibodies to a high-molecular-weight MAA [12] as well as the results here with MoAb 345.134S indicate that the level of expression of tumor-associated antigens as well as the susceptibility of melanoma cells to immune lysis mediated by monoclonal antibodies to these structures are not increased by interferon treatment. These data suggest that if immunological factors play any role in the reported therapeutic effects of interferon on melanoma, they occur by routes other than increased expression of tumor-associated antigens, at least those identified by the monoclonal antibodies we have developed.
